Liraglutide injection into the VMH of mice induced weight loss and increased thermogenetic activity, as evidenced by elevated uncoupling protein 1 expression in both BAT and white adipose tissue, with adenosine monophosphate-activated protein kinase (AMPK) signaling in the VMH required as a mediator [71]
These include persistent insomnia, significant changes in appetite beyond expected medication effects, difficulty concentrating that impairs function, or physical symptoms such as chest pain or palpitations during emotional episodes
Zinc: protecting immune function and metabolism Research on GLP-1 users found significant decreases in serum zinc levels alongside weight reduction
5 So that begs the answer to the question, is GLP-1 microdosing an option to maintain a healthy weight in perimenopause? While GLP-1 popularity in brands like Ozempic has surged, with benefits being tied to the FDA-recommended dosages, researchers have documented growing interest in GLP-1 microdosing a term that may describe two distinct practices: 6 Standard, physician-guided dose adjustments Off-label use of GLP-1 drugs at doses lower than those the FDA recommends The idea, publications explain, is for individuals to reap the benefits of GLP-1s with reduced side effects, which may include: 7 Nausea Vomiting Diarrhea Headache Experts believe the concept of GLP-1 microdosing may have stemmed from obesity drug shortages in 2021 and 2022
Tidal Wave of Litigation: Multiple lawsuits filed against Novo Nordisk and Eli Lilly have alleged that manufacturers failed to adequately warn patients and healthcare providers about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) and other vision-related complications associated with their products
